Recoverin-IgG Antibody, Immunoblot, Serum
Use
This test is useful for evaluating patients with suspected paraneoplastic retinopathy accompanying small cell carcinoma. Patients with recoverin autoimmunity typically present with insidious onset of vision changes such as night-vision loss, floaters, and constricted vision, possibly progressing rapidly to blindness. Ophthalmologic examinations often reveal non-inflammatory retinopathy, and small cell or neuroendocrine carcinoma may be suggested by the findings.
Special Instructions
Not provided.
Limitations
A negative result does not exclude the possibility of paraneoplastic retinopathy, other autoimmune retinopathy, or cancer. The test was developed in a manner consistent with CLIA requirements, but it has not been cleared or approved by the FDA. Also, the presence of other antibodies, such as CRMP-5, may be associated with paraneoplastic retinopathy, which this test does not detect.
New York Approved
Methodology
Immunoassay (Other)
Biomarkers
LOINC Codes
- 83003-4 - Recoverin IgG SerPl Ql Line blot
- 83003-4 - Recoverin IgG SerPl Ql Line blot
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
Not provided
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |